Prostatype Genomics AB (publ) (STO:PROGEN)

Market Cap	57.77M +84.9%
Revenue (ttm)	594.00K -69.0%
Net Income	-44.50M
EPS	-1.32
Shares Out	59.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,894
Average Volume	196,452
Open	0.9520
Previous Close	0.9900
Day's Range	0.9160 - 0.9820
52-Week Range	0.2800 - 5.6600
Beta	1.94
RSI	46.23
Earnings Date	May 13, 2026

About Prostatype Genomics AB

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 6
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PROGEN

Financial Performance

In 2025, Prostatype Genomics AB's revenue was 594,000, a decrease of -69.03% compared to the previous year's 1.92 million. Losses were -44.50 million, 8.41% more than in 2024.